CanSino Biologics Inc. (6185) informed shareholders of its plan to hold the 2025 second extraordinary general meeting on November 27, 2025, in Tianjin, where multiple proposals will be reviewed and voted upon.

Key motions include a proposal to cancel the Board of Supervisors and make corresponding amendments to the Company’s articles of association and other procedural rules. In addition, amendments to several corporate governance rules are tabled, covering funds management and related party transactions, among others.

The meeting will also consider a plan to utilize reserves to offset historical losses. Another highlight is the proposed appointment of two independent non-executive directors, who are nominated pending shareholder approval at the upcoming meeting.

The Company reminds eligible shareholders to review the details of these proposals and attend or appoint proxies in accordance with relevant instructions by November 26, 2025.